Is MET a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Group Benefits and workplace demand, with revenue (ttm) at ~$79.4 billion, up ~10.5% YoY in Q2 2026. The bear case rests on metLife's biggest risks come from the same levers that drive its profits. Analysts covering it are spread from $84.00 to $119.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. MetLife's biggest risks come from the same levers that drive its profits. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $84.00, -16.6% from the $100.76 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Group Benefits and workplace demand. Group Benefits is a scale business where MetLife sells life, dental, disability, and supplemental coverage through employers. The most optimistic analyst target on MET is $119.00, +18.1% from the $100.76 price. That figure is only reachable if this thesis works close to its best case.

MetLife's biggest risks come from the same levers that drive its profits. As a large investor of policyholder float, it is exposed to interest-rate swings, credit spreads, and equity-market moves: sharp rate changes affect both investment income and the value of long-duration liabilities, and a credit downturn could pressure its bond and commercial-real-estate holdings. Insurance-specific risks include mortality, morbidity, and longevity assumptions proving wrong, plus reserve adequacy on long-tail liabilities like pensions and annuities. Its international earnings add currency and local-regulatory risk. Reported net income can be lumpy because of actuarial assumption updates, derivative marks, and market-related items, which is why the company emphasizes adjusted earnings. Insurance is also heavily regulated and capital-intensive, so statutory capital requirements and rating-agency views constrain how much can be returned to shareholders. After a 27% rise in 2026 the shares sit close to the analyst mean target of about $107 (October 2026), so less of the capital-return story is left unpriced than a year ago. The most pessimistic published target is $84.00, -16.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Group Benefits and workplace demand) stalling in the reported numbers rather than in the narrative, the risk above (metLife's biggest risks come from the same levers that drive its profits) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a large, diversified insurer with strong free cash flow, rising adjusted earnings, a long-standing and growing dividend, and heavy buybacks. The bear case is sensitivity to interest rates and credit markets, lumpy reported earnings, long-tail insurance liabilities, and modest top-line growth. Weigh both against your own portfolio and needs.

MetLife is one of the world's largest life insurers and employee-benefits companies. It sells group life, disability, and dental coverage through employers, retirement and income products like annuities and pension risk transfers, and life and health insurance across Asia, Latin America, and other regions. It earns money both by underwriting insurance and by investing the premiums it collects.

Yes. MetLife pays a regular quarterly dividend and has a long history of returning capital to shareholders. In 2026 it raised the quarterly dividend by about 4.4% to $0.5925 per share and extended its buyback program. That works out to about $2.37 a year and a yield near 2.4% at the October 16, 2026 price of about $101.80, with a payout around 44% of trailing GAAP earnings.